



July 17, 2012

Johnson & Johnson Reports 2012 Second-Quarter Results: Sales of \$16.5 Billion decreased 0.7% Versus 2011 Second Quarter; Second-Quarter EPS was \$0.50 Excluding Special Items, 2012 Second-Quarter EPS of \$1.30 increased 1.6%*

NEW BRUNSWICK, N.J., July 17, 2012 /PRNewswire/ -- Johnson & Johnson today announced sales of \$16.5 billion for the second quarter of 2012, a decrease of 0.7% as compared to the second quarter of 2011. Operational results increased 3.5% and the negative impact of currency was 4.2%. Domestic sales decreased 1.2%. International sales decreased 0.4%, reflecting operational growth of 7.1% and a negative currency impact of 7.5%. Sales included the impact of the recently completed acquisition of Synthes, Inc., which contributed 1.2% to worldwide operational sales growth.

Net earnings and diluted earnings per share for the second quarter of 2012 were \$1.4 billion and \$0.50, respectively. Second-quarter 2012 net earnings include after-tax special items of \$2.2 billion, consisting of non-cash charges primarily attributed to a partial write-down of in-process research and development and intangible assets related to the Crucell vaccines business, an increase in the accrual for the potential settlement of previously disclosed civil litigation matters, and transaction and integration costs related to the acquisition of Synthes, Inc. Second-quarter 2011 net earnings included after-tax special items of \$772 million, consisting of net charges related to the restructuring by Cordis Corporation, the net impact of expenses related to litigation, DePuy ASR™ Hip recall costs, and currency adjustment related to the acquisition of Synthes, Inc. Excluding these special items, net earnings for the current quarter were \$3.6 billion and diluted earnings per share were \$1.30, representing increases of 2.7% and 1.6%, respectively, as compared to the same period in 2011.*

"Our talented associates around the world are building a strong foundation for sustainable growth through meaningful innovations and an expanding global footprint. Our pharmaceutical pipeline continued its strong momentum this quarter with the submission of several new drug applications, as well as strong growth from several recently launched products that meet critical patient needs," said Alex Gorsky, Chief Executive Officer. "The completion of the Synthes acquisition also marks an important milestone in strengthening our leadership in key health care markets, creating a powerful portfolio of orthopaedic and neurological solutions to advance patient health and well-being," said Gorsky.

The Company adjusted its earnings guidance for full-year 2012 to \$5.00 - \$5.07 per share. The Company's guidance excludes the impact of special items and reflects the negative impact of recent currency movements, partially offset by the positive contribution from the Synthes acquisition.

Worldwide Consumer sales of \$3.6 billion for the second quarter represented a decrease of 4.6% versus the prior year consisting of an operational increase of 0.6% and a negative impact from currency of 5.2%. Domestic sales decreased 1.9%. International sales decreased 6.0%, which reflected an operational increase of 2.0% and a negative currency impact of 8.0%.

Positive contributors to operational results were international sales of oral care products; NEUTROGENA® skin care products; and international baby care products.

Worldwide Pharmaceutical sales of \$6.3 billion for the second quarter represented an increase of 0.9% versus the prior year with operational growth of 5.1% and a negative impact from currency of 4.2%. Domestic sales decreased 4.5%. International sales increased 6.8%, which reflected an operational increase of 15.5% and a negative currency impact of 8.7%.

Positive contributors to international sales were strong results for REMICADE® (infliximab), a biologic approved for the treatment of a number of immune-mediated, inflammatory diseases, primarily related to incremental sales from international territories included in the amended distribution agreement with Merck; PREZISTA® (darunavir), a treatment for HIV; and sales of recently launched products.

The strong sales results of recently launched products include ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone, for the treatment of metastatic, castration-resistant prostate cancer; INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the acute and maintenance treatment of schizophrenia in adults; international sales of INCIVO® (telaprevir), a direct acting antiviral protease inhibitor, for the treatment of genotype-1 chronic hepatitis C virus, in combination with peginterferon alfa and ribavirin, in adults; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; and XARELTO® (rivaroxaban), an oral anticoagulant.

Sales results in the U.S. were negatively impacted by generic competition for LEVAQUIN® (levofloxacin), a treatment for bacterial infections, and the manufacturing suspension at a third party supplier for DOXIL® (doxorubicin HCl liposome injection)/CAELYX® (pegylated liposomal doxorubicin hydrochloride), a medication to treat ovarian and other cancers.

During the quarter, several drug marketing applications were submitted in the U.S. and European Union. These included a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval for the use of canagliflozin, an oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes. A supplemental NDA was submitted to the FDA and a type II

variation to the EMA to extend the use of ZYTIGA® (abiraterone acetate) administered with prednisone to include the treatment of patients with metastatic castration resistant prostate cancer who have not received chemotherapy. Supplemental NDAs were also submitted to the FDA seeking approval for the use of XARELTO® (rivaroxaban) to treat patients with deep vein thrombosis or pulmonary embolism and prevention of recurrent venous thromboembolism. In addition, an NDA was submitted to the FDA seeking accelerated approval for the use of bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis in adults.

Also during the quarter, Janssen-Cilag GmbH completed the acquisition of Corlmmun GmbH, a privately held drug development company in Germany, whose lead compound, COR-1, is a small cyclic peptide currently in early clinical development for the treatment of heart failure.

Worldwide Medical Devices and Diagnostics sales of \$6.6 billion for the second quarter represented a decrease of 0.1% versus the prior year consisting of an operational increase of 3.4% and a negative currency impact of 3.5%. Domestic sales increased 2.9%. International sales decreased 2.4%, which reflected an operational increase of 3.8% and a negative currency impact of 6.2%. Sales included the impact of the recently completed acquisition of Synthes, Inc., which contributed 2.9%, 3.7%, and 2.3% to worldwide, domestic and international operational sales growth, respectively.

Primary contributors to operational growth were orthopaedic sales from the recently completed acquisition of Synthes; Biosense Webster's electrophysiology products in our Cardiovascular Care business; Ethicon's wound care products in our General Surgery business; LifeScan's blood glucose monitoring products in our Diabetes Care business; and international sales of energy products in our Specialty Surgery business. The growth was impacted by lower sales in the Cardiovascular Care business, reflecting the decision to exit the drug eluting stent market at the end of the second quarter of 2011.

During the quarter, the Company announced the completion of the acquisition of Synthes for \$19.7 billion in cash and stock, creating the world's most innovative and comprehensive orthopaedics business. In connection with the Synthes acquisition, DePuy Orthopaedics, Inc. agreed to divest its trauma business to Biomet, Inc. and completed the initial closing for this transaction, including those countries that represented the majority of sales.

In addition, Johnson & Johnson (China) Investment Ltd. completed its first medical device acquisition in China - the purchase of Guangzhou Bioseal Biotech Co., Ltd., a privately held biopharmaceutical company specializing in the design, development and commercialization of a porcine plasma-derived biologic product for controlling bleeding during surgery.

About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company's website at www.investor.jnj.com.

NOTE TO INVESTORS

Johnson & Johnson will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, condensed consolidated statements of earnings, and sales of key products/franchises.

Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and medical devices and diagnostics pipeline of selected products, can be found on the Company's website at www.jnj.com

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)		SECOND QUARTER					SIX MONTHS					
				Percent Change					Percent Change			
		2012	2011	Total	Operations	Currency	2012	2011	Total	Operations	Currency	
Sales to customers by segment of business												
Consumer												
U.S.	\$	1,313	1,339	(1.9) %	(1.9)	-	\$	2,629	2,684	(2.0) %	(2.0)	-
International		2,306	2,454	(6.0)	2.0	(8.0)		4,585	4,791	(4.3)	1.2	(5.5)
		3,619	3,793	(4.6)	0.6	(5.2)		7,214	7,475	(3.5)	-	(3.5)
Pharmaceutical												
U.S.		3,094	3,239	(4.5)	(4.5)	-		6,120	6,630	(7.7)	(7.7)	-
International		3,197	2,994	6.8	15.5	(8.7)		6,304	5,662	11.3	17.3	(6.0)
		6,291	6,233	0.9	5.1	(4.2)		12,424	12,292	1.1	3.9	(2.8)
Med Devices & Diagnostics												
U.S.		2,953	2,869	2.9	2.9	-		5,830	5,741	1.6	1.6	-
International		3,612	3,702	(2.4)	3.8	(6.2)		7,146	7,262	(1.6)	2.2	(3.8)
		6,565	6,571	(0.1)	3.4	(3.5)		12,976	13,003	(0.2)	1.9	(2.1)
U.S.		7,360	7,447	(1.2)	(1.2)	-		14,579	15,055	(3.2)	(3.2)	-
International		9,115	9,150	(0.4)	7.1	(7.5)		18,035	17,715	1.8	6.8	(5.0)
Worldwide	\$	16,475	16,597	(0.7) %	3.5	(4.2)	\$	32,614	32,770	(0.5) %	2.2	(2.7)

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)		SECOND QUARTER					SIX MONTHS					
				Percent Change					Percent Change			
		2012	2011	Total	Operations	Currency	2012	2011	Total	Operations	Currency	
Sales to customers by geographic area												
U.S.	\$	7,360	7,447	(1.2) %	(1.2)	-	\$	14,579	15,055	(3.2) %	(3.2)	-
Europe		4,165	4,543	(8.3)	1.6	(9.9)		8,359	8,726	(4.2)	2.9	(7.1)
Western Hemisphere excluding U.S.		1,728	1,543	12.0	22.4	(10.4)		3,442	2,979	15.5	22.7	(7.2)
Asia-Pacific, Africa		3,222	3,064	5.2	7.7	(2.5)		6,234	6,010	3.7	4.5	(0.8)
International		9,115	9,150	(0.4)	7.1	(7.5)		18,035	17,715	1.8	6.8	(5.0)
Worldwide	\$	16,475	16,597	(0.7) %	3.5	(4.2)	\$	32,614	32,770	(0.5) %	2.2	(2.7)

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

SECOND QUARTER

2012	2011	Percent Increase
Percent	Percent	

	Amount	to Sales	Amount	to Sales	(Decrease)
Sales to customers	\$ 16,475	100.0	\$ 16,597	100.0	(0.7)
Cost of products sold	5,143	31.2	5,172	31.2	(0.6)
Selling, marketing and administrative expenses	4,965	30.1	5,215	31.4	(4.8)
Research and development expense	1,766	10.7	1,882	11.3	(6.2)
In-process research and development	429	2.6	-	-	
Interest (income) expense, net	129	0.8	111	0.7	
Other (income) expense, net	2,008	12.2	206	1.3	
Restructuring expense	-	-	589	3.5	
Earnings before provision for taxes on income	2,035	12.4	3,422	20.6	(40.5)
Provision for taxes on income	627	3.9	646	3.9	(2.9)
Net earnings	\$ 1,408	8.5	\$ 2,776	16.7	(49.3)
Net earnings per share (Diluted)	\$ 0.50		\$ 1.00		(50.0)
Average shares outstanding (Diluted)	2,798.2		2,781.3		
Effective tax rate	30.8 %		18.9 %		

Adjusted earnings before provision for taxes and net earnings (1)					
Earnings before provision for taxes on income	\$ 4,646	28.2	\$ 4,413	26.6	5.3
Net earnings	\$ 3,644	22.1	\$ 3,548	21.4	2.7
Net earnings per share (Diluted)	\$ 1.30		\$ 1.28		1.6
Effective tax rate	21.6 %		19.6 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

	SIX MONTHS				
	2012		2011		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 32,614	100.0	\$ 32,770	100.0	(0.5)
Cost of products sold	10,058	30.8	9,950	30.4	1.1
Selling, marketing and administrative expenses	9,980	30.6	10,271	31.3	(2.8)
Research and development expense	3,411	10.5	3,620	11.0	(5.8)
In-process research and development	429	1.3	-	-	
Interest (income) expense, net	259	0.8	215	0.7	
Other (income) expense, net	1,397	4.3	193	0.6	
Restructuring expense	-	-	589	1.8	
Earnings before provision for taxes on income	7,080	21.7	7,932	24.2	(10.7)
Provision for taxes on income	1,762	5.4	1,680	5.1	4.9
Net earnings	\$ 5,318	16.3	\$ 6,252	19.1	(14.9)
Net earnings per share (Diluted)	\$ 1.91		\$ 2.25		(15.1)
Average shares outstanding (Diluted)	2,792.4		2,778.1		
Effective tax rate	24.9 %		21.2 %		
Adjusted earnings before provision for taxes and net earnings (1)					
Earnings before provision for taxes on income	\$ 9,574	29.4	\$ 9,269	28.3	3.3
Net earnings	\$ 7,448	22.8	\$ 7,295	22.3	2.1
Net earnings per share (Diluted)	\$ 2.67		\$ 2.63		1.5
Effective tax rate	22.2 %		21.3 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

Reconciliation of Non-GAAP Financial Measures

<i>(Dollars in Millions Except Per Share Data)</i>	Second Quarter			%Incr. / (Decr.)	Six Months YTD		
	2012	2011			2012	2011	%Incr. / (Decr.)
Earnings before provision for taxes on income - as reported	\$ 2,035	3,422	(40.5) %	\$ 7,080	\$ 7,932	(10.7) %	
Intangible asset write-downs	939	-		939	-		
Net litigation	669	315		669	576		
Synthes integration/transaction costs and currency related	574	(102)		457	(102)		
In-process research and development	429	-		429	-		
Restructuring - Cordis	-	676		-	676		
DePuy ASR™Hip related costs	-	102		-	187		
Earnings before provision for taxes on income - as adjusted	\$ 4,646	4,413	5.3 %	\$ 9,574	9,269	3.3 %	
Net Earnings - as reported	\$ 1,408	2,776	(49.3) %	\$ 5,318	6,252	(14.9) %	
Intangible asset write-downs	717	-		717	-		
Net litigation	611	242		611	444		
Synthes integration/transaction costs and currency related	564	(102)		458	(102)		
In-process research and development	344	-		344	-		
Restructuring - Cordis	-	549		-	549		
DePuy ASR™Hip related costs	-	83		-	152		
Net Earnings - as adjusted	\$ 3,644	3,548	2.7 %	\$ 7,448	7,295	2.1 %	
Diluted Net Earnings per share - as reported	\$ 0.50	1.00	(50.0) %	\$ 1.91	2.25	(15.1) %	
Intangible asset write-downs	0.26	-		0.26	-		
Net litigation	0.22	0.09		0.22	0.16		
Synthes integration/transaction costs and currency related	0.20	(0.04)		0.16	(0.04)		
In-process research and development	0.12	-		0.12	-		
Restructuring - Cordis	-	0.20		-	0.20		
DePuy ASR™Hip related costs	-	0.03		-	0.06		
Diluted Net Earnings per share - as adjusted	\$ 1.30	1.28	1.6 %	\$ 2.67	2.63	1.5 %	

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2012	2011	% Change			2012	2011	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
CONSUMER SEGMENT (2)										
BABY CARE										
US	\$ 106	105	1.0%	1.0%	-	\$ 205	210	-2.4%	-2.4%	-

Intl	472	493	-4.3%	3.5%	-7.8%	913	949	-3.8%	1.7%	-5.5%
WW	578	598	-3.3%	3.2%	-6.5%	1,118	1,159	-3.5%	1.0%	-4.5%
ORAL CARE										
US	159	158	0.6%	0.6%	-	314	321	-2.2%	-2.2%	-
Intl	249	241	3.3%	11.9%	-8.6%	481	469	2.6%	8.5%	-5.9%
WW	408	399	2.3%	7.5%	-5.2%	795	790	0.6%	4.1%	-3.5%
OTC/NUTRITIONALS										
US	336	330	1.8%	1.8%	-	717	727	-1.4%	-1.4%	-
Intl	696	753	-7.6%	0.1%	-7.7%	1,419	1,485	-4.4%	0.9%	-5.3%
WW	1,032	1,083	-4.7%	0.6%	-5.3%	2,136	2,212	-3.4%	0.2%	-3.6%
SKIN CARE										
US	471	449	4.9%	4.9%	-	924	875	5.6%	5.6%	-
Intl	442	480	-7.9%	-0.3%	-7.6%	896	953	-6.0%	-1.0%	-5.0%
WW	913	929	-1.7%	2.2%	-3.9%	1,820	1,828	-0.4%	2.2%	-2.6%
WOMEN'S HEALTH										
US	80	121	-33.9%	-33.9%	-	173	246	-29.7%	-29.7%	-
Intl	322	356	-9.6%	-0.2%	-9.4%	638	690	-7.5%	-0.8%	-6.7%
WW	402	477	-15.7%	-8.7%	-7.0%	811	936	-13.4%	-8.5%	-4.9%
WOUND CARE/OTHER										
US	161	176	-8.5%	-8.5%	-	296	305	-3.0%	-3.0%	-
Intl	125	131	-4.6%	2.8%	-7.4%	238	245	-2.9%	2.3%	-5.2%
WW	286	307	-6.8%	-3.7%	-3.1%	534	550	-2.9%	-0.6%	-2.3%
TOTAL CONSUMER										
US	1,313	1,339	-1.9%	-1.9%	-	2,629	2,684	-2.0%	-2.0%	-
Intl	2,306	2,454	-6.0%	2.0%	-8.0%	4,585	4,791	-4.3%	1.2%	-5.5%
WW	\$ 3,619	3,793	-4.6%	0.6%	-5.2%	\$ 7,214	7,475	-3.5%	0.0%	-3.5%

See footnotes at end of schedule

	SECOND QUARTER					SIX MONTHS				
	2012	2011	% Change			2012	2011	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
PHARMACEUTICAL SEGMENT										
(2) (4)										
IMMUNOLOGY										
US	\$ 1,471	1,524	-3.5%	-3.5%	-	\$ 2,924	2,960	-1.2%	-1.2%	-
Intl	448	131	*	*	-8.1%	890	275	*	*	-5.2%
WW	1,919	1,655	16.0%	18.2%	-2.2%	3,814	3,235	17.9%	19.1%	-1.2%
REMICADE										
US	890	836	6.5%	6.5%	-	1,772	1,624	9.1%	9.1%	-
US Exports ⁽³⁾	366	527	-30.6%	-30.6%	-	744	1,017	-26.8%	-26.8%	-
Intl	267	8	*	*	-8.3%	528	15	*	*	-5.3%
WW	1,523	1,371	11.1%	12.7%	-1.6%	3,044	2,656	14.6%	15.6%	-1.0%
SIMPONI										
US	63	61	3.3%	3.3%	-	127	114	11.4%	11.4%	-
Intl	62	6	*	*	-5.8%	114	48	*	*	-8.6%
WW	125	67	86.6%	89.5%	-2.9%	241	162	48.8%	51.3%	-2.5%
STELARA										
US	152	100	52.0%	52.0%	-	281	205	37.1%	37.1%	-
Intl	96	76	26.3%	35.1%	-8.8%	188	137	37.2%	45.5%	-8.3%
WW	248	176	40.9%	45.7%	-4.8%	469	342	37.1%	40.4%	-3.3%
OTHER IMMUNOLOGY										
US	-	-	-	-	-	-	-	-	-	-
Intl	23	41	-43.9%	-39.2%	-4.7%	60	75	-20.0%	-16.6%	-3.4%
WW	23	41	-43.9%	-39.2%	-4.7%	60	75	-20.0%	-16.6%	-3.4%
INFECTIOUS DISEASES										
US	237	351	-32.5%	-32.5%	-	479	975	-50.9%	-50.9%	-
Intl	551	477	15.5%	26.0%	-10.5%	1,064	784	35.7%	44.3%	-8.6%
WW	788	828	-4.8%	1.3%	-6.1%	1,543	1,759	-12.3%	-8.5%	-3.8%
INTELENCE										
US	42	38	10.5%	10.5%	-	85	76	11.8%	11.8%	-
Intl	49	41	19.5%	30.4%	-10.9%	86	72	19.4%	27.4%	-8.0%
WW	91	79	15.2%	20.8%	-5.6%	171	148	15.5%	19.4%	-3.9%
LEVAQUIN/FLOXIN										
US	7	149	-95.3%	-95.3%	-	25	571	-95.6%	-95.6%	-

Intl	9	10	-10.0%	-2.7%	-7.3%	20	22	-9.1%	-3.9%	-5.2%
WW	16	159	-89.9%	-89.4%	-0.5%	45	593	-92.4%	-92.2%	-0.2%
<u>PREZISTA</u>										
US	166	128	29.7%	29.7%	-	326	254	28.3%	28.3%	-
Intl	207	185	11.9%	22.6%	-10.7%	371	325	14.2%	22.2%	-8.0%
WW	373	313	19.2%	25.5%	-6.3%	697	579	20.4%	24.9%	-4.5%
<u>OTHER INFECTIOUS DISEASES</u>										
US	22	36	-38.9%	-38.9%	-	43	74	-41.9%	-41.9%	-
Intl	286	241	18.7%	29.1%	-10.4%	587	365	60.8%	70.3%	-9.5%
WW	308	277	11.2%	20.2%	-9.0%	630	439	43.5%	51.4%	-7.9%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2012	2011	% Change			2012	2011	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
NEUROSCIENCE										
US	658	684	-3.8%	-3.8%	-	1,332	1,372	-2.9%	-2.9%	-
Intl	1,056	1,096	-3.6%	3.2%	-6.8%	2,029	2,153	-5.8%	-1.3%	-4.5%
WW	1,714	1,780	-3.7%	0.5%	-4.2%	3,361	3,525	-4.7%	-1.9%	-2.8%
<u>CONCERTA/METHYLPHENIDATE</u>										
US	146	234	-37.6%	-37.6%	-	343	488	-29.7%	-29.7%	-
Intl	122	115	6.1%	14.0%	-7.9%	233	223	4.5%	10.1%	-5.6%
WW	268	349	-23.2%	-20.6%	-2.6%	576	711	-19.0%	-17.2%	-1.8%
<u>INVEGA</u>										
US	76	76	0.0%	0.0%	-	145	145	0.0%	0.0%	-
Intl	66	52	26.9%	33.6%	-6.7%	118	103	14.6%	18.8%	-4.2%
WW	142	128	10.9%	13.6%	-2.7%	263	248	6.0%	7.8%	-1.8%
<u>INVEGA SUSTENNA/ XEPLION</u>										
US	120	70	71.4%	71.4%	-	220	135	63.0%	63.0%	-
Intl	75	7	*	*	-8.8%	136	7	*	*	-6.2%
WW	195	77	*	*	-3.4%	356	142	*	*	-2.4%
<u>RISPERDAL CONSTA</u>										
US	110	110	0.0%	0.0%	-	223	224	-0.4%	-0.4%	-
Intl	245	294	-16.7%	-9.3%	-7.4%	493	584	-15.6%	-10.5%	-5.1%
WW	355	404	-12.1%	-6.7%	-5.4%	716	808	-11.4%	-7.7%	-3.7%
<u>OTHER NEUROSCIENCE</u>										
US	206	194	6.2%	6.2%	-	401	380	5.5%	5.5%	-
Intl	548	628	-12.7%	-7.3%	-5.4%	1,049	1,236	-15.1%	-11.7%	-3.4%
WW	754	822	-8.3%	-4.2%	-4.1%	1,450	1,616	-10.3%	-7.7%	-2.6%
ONCOLOGY										
US	119	93	28.0%	28.0%	-	226	157	43.9%	43.9%	-
Intl	467	459	1.7%	11.2%	-9.5%	956	834	14.6%	21.8%	-7.2%
WW	586	552	6.2%	14.1%	-7.9%	1,182	991	19.3%	25.3%	-6.0%
<u>DOXIL/CAELYX</u>										
US	6	56	-89.3%	-89.3%	-	13	120	-89.2%	-89.2%	-
Intl	7	82	-91.5%	-89.9%	-1.6%	24	157	-84.7%	-83.4%	-1.3%
WW	13	138	-90.6%	-89.7%	-0.9%	37	277	-86.6%	-85.9%	-0.7%
<u>VELCADE</u>										
US	-	-	-	-	-	-	-	-	-	-
Intl	318	347	-8.4%	-0.1%	-8.3%	671	627	7.0%	13.4%	-6.4%
WW	318	347	-8.4%	-0.1%	-8.3%	671	627	7.0%	13.4%	-6.4%
<u>ZYTIGA</u>										
US	113	37	*	*	-	213	37	*	*	-
Intl	119	12	*	*	-10.0%	219	17	*	*	-7.1%
WW	232	49	*	*	-5.1%	432	54	*	*	-3.6%
<u>OTHER ONCOLOGY</u>										
US	-	-	-	-	-	-	-	-	-	-
Intl	23	18	27.8%	36.4%	-8.6%	42	33	27.3%	33.2%	-5.9%
WW	23	18	27.8%	36.4%	-8.6%	42	33	27.3%	33.2%	-5.9%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

SECOND QUARTER	SIX MONTHS
----------------	------------

	% Change					% Change				
	2012	2011	Reported	Operational ⁽¹⁾	Currency	2012	2011	Reported	Operational ⁽¹⁾	Currency
TOTAL OTHER										
US	609	587	3.7%	3.7%	-	1,159	1,166	-0.6%	-0.6%	-
Intl	675	831	-18.8%	-11.8%	-7.0%	1,365	1,616	-15.5%	-10.9%	-4.6%
WW	1,284	1,418	-9.4%	-5.3%	-4.1%	2,524	2,782	-9.3%	-6.6%	-2.7%
ACIPHEX/PARIET										
US	104	101	3.0%	3.0%	-	200	210	-4.8%	-4.8%	-
Intl	128	146	-12.3%	-2.8%	-9.5%	254	276	-8.0%	-1.5%	-6.5%
WW	232	247	-6.1%	-0.5%	-5.6%	454	486	-6.6%	-2.9%	-3.7%
PROCRI/EPREX										
US	232	257	-9.7%	-9.7%	-	436	447	-2.5%	-2.5%	-
Intl	169	218	-22.5%	-14.9%	-7.6%	341	425	-19.8%	-14.5%	-5.3%
WW	401	475	-15.6%	-12.1%	-3.5%	777	872	-10.9%	-8.3%	-2.6%
OTHER										
US	273	229	19.2%	19.2%	-	523	509	2.8%	2.8%	-
Intl	378	467	-19.1%	-13.2%	-5.9%	770	915	-15.8%	-12.1%	-3.7%
WW	651	696	-6.5%	-2.6%	-3.9%	1,293	1,424	-9.2%	-6.8%	-2.4%
TOTAL PHARMACEUTICAL										
US	3,094	3,239	-4.5%	-4.5%	-	6,120	6,630	-7.7%	-7.7%	-
Intl	3,197	2,994	6.8%	15.5%	-8.7%	6,304	5,662	11.3%	17.3%	-6.0%
WW	\$ 6,291	6,233	0.9%	5.1%	-4.2%	\$ 12,424	12,292	1.1%	3.9%	-2.8%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2012	2011	% Change			2012	2011	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
MEDICAL DEVICES AND DIAGNOSTICS ⁽²⁾⁽⁴⁾										
CARDIOVASCULAR CARE										
US	\$ 195	210	-7.1%	-7.1%	-	\$ 371	452	-17.9%	-17.9%	-
Intl	309	377	-18.0%	-13.1%	-4.9%	615	770	-20.1%	-17.2%	-2.9%
WW	504	587	-14.1%	-10.9%	-3.2%	986	1,222	-19.3%	-17.5%	-1.8%
DIABETES CARE										
US	337	333	1.2%	1.2%	-	689	644	7.0%	7.0%	-
Intl	336	348	-3.4%	4.6%	-8.0%	654	674	-3.0%	2.5%	-5.5%
WW	673	681	-1.2%	2.9%	-4.1%	1,343	1,318	1.9%	4.7%	-2.8%
DIAGNOSTICS										
US	258	281	-8.2%	-8.2%	-	511	546	-6.4%	-6.4%	-
Intl	256	269	-4.8%	0.8%	-5.6%	515	525	-1.9%	1.6%	-3.5%
WW	514	550	-6.5%	-3.8%	-2.7%	1,026	1,071	-4.2%	-2.5%	-1.7%
GENERAL SURGERY										
US	602	621	-3.1%	-3.1%	-	1,195	1,217	-1.8%	-1.8%	-
Intl	1,038	1,079	-3.8%	3.1%	-6.9%	2,070	2,104	-1.6%	2.8%	-4.4%
WW	1,640	1,700	-3.5%	0.9%	-4.4%	3,265	3,321	-1.7%	1.1%	-2.8%
INFECTION PREVENTION/OTHER										
US	99	98	1.0%	1.0%	-	215	193	11.4%	11.4%	-
Intl	131	134	-2.2%	3.3%	-5.5%	259	255	1.6%	4.8%	-3.2%
WW	230	232	-0.9%	2.3%	-3.2%	474	448	5.8%	7.6%	-1.8%
ORTHOPAEDICS										
US	873	770	13.4%	13.4%	-	1,656	1,581	4.7%	4.7%	-
Intl	755	699	8.0%	14.8%	-6.8%	1,465	1,391	5.3%	9.5%	-4.2%
WW	1,628	1,469	10.8%	14.0%	-3.2%	3,121	2,972	5.0%	6.9%	-1.9%
SPECIALTY SURGERY										
US	336	311	8.0%	8.0%	-	663	607	9.2%	9.2%	-
Intl	310	309	0.3%	7.6%	-7.3%	611	590	3.6%	8.4%	-4.8%
WW	646	620	4.2%	7.8%	-3.6%	1,274	1,197	6.4%	8.8%	-2.4%
VISION CARE										
US	253	245	3.3%	3.3%	-	530	501	5.8%	5.8%	-
Intl	477	487	-2.1%	1.2%	-3.3%	957	953	0.4%	1.9%	-1.5%
WW	730	732	-0.3%	1.9%	-2.2%	1,487	1,454	2.3%	3.3%	-1.0%

**TOTAL MEDICAL DEVICES
AND DIAGNOSTICS**

US	2,953	2,869	2.9%	2.9%	-
Intl	3,612	3,702	-2.4%	3.8%	-6.2%
WW	\$ 6,565	6,571	-0.1%	3.4%	-3.5%

5,830	5,741	1.6%	1.6%	-
7,146	7,262	-1.6%	2.2%	-3.8%
\$ 12,976	13,003	-0.2%	1.9%	-2.1%

* Percentage greater than 100%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Reported as U.S. sales

(4) Prior year amounts have been reclassified to conform to current year product disclosure

SOURCE Johnson & Johnson

News Provided by Acquire Media